79407-24-2

Upstream product

• 79407-28-6 5-{2-[Benzyl-(2-hydroxy-4-o-tolyl-butyl)-amino]-ethoxy}-2-hydroxy-benzamide 
• 56812-61-4 2-methylbenzylmagnesium bromide 
• 76813-69-9 5-[2-(benzylamino)-ethoxy]-salicylamide 
• 52405-73-9 gentisamide 
• 74454-60-7 2,3-dihydro-2,2-dimethyl-6-(2-bromoethoxy)-4H-1,3-benzoxazin-4-one 
• 74469-70-8 2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-one 
• 79407-26-4 1-chloro-4-(2-methylphenyl)-2-butanol 
• 79407-27-5 1,2-epoxy-4-(2-methylphenyl)butane 

Relevant academic research and scientific papers

β-Adrenergic blocking agents: Substituted phenylalkanolamines. Effect of side-chain length on β-blocking potency in vitro

The synthesis of a group of potential β-blockers bearing a new 5-ethoxysalicylamide substituent on nitrogen is described. These compounds were tested for β-adrenergic blocking potency in vitro and compared with analogous compounds bearing a tert-butyl group on nitrogen. The new N-substituent increased the β-blocking potency substantially. In a series of five homologous compounds of the type Ar(CH2)(n)CHOHCH2NHR (R = 5-ethoxysalicylamide; n = 0-4), two maxima of β-blocking potency were found for n = 0 and 2. Moreover, the carbon isostere of the corresponding (aryloxy)propanolamine still proved to be a very potent β-blocker. The ether oxygen in the side chain is therefore not an absolute requirement for activity. Structure-activity relationships are discussed.